Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks

Population Health Management

Volumn 16, Issue 2, 2013, Pages 138-145

  Lynch, Wendy ^a   Chan, Wing ^b   Kleinman, Nathan ^a   Andrews, L M ^b   Yadao, Anthony M ^b  

^a Human Capital Management Services   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT;

ABSENTEEISM; ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; EMERGENCY CARE; EMPLOYEE; FEMALE; GOUT; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; OUTCOME ASSESSMENT; PHYSICAL DISABILITY;

ARTHRITIS, GOUTY; COST OF ILLNESS; DATABASES, FACTUAL; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SICK LEAVE; UNITED STATES;

EID: 84876126532     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2012.0057     Document Type: Article

References (25)

1. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. Rheumatology 2004;31:1582-1587.
2. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59:925-934.
3. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA 1991;266:3004-3007.
4. Adams PF, Hendershot GE, Marano MA; Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 1999;200:1-203.
5. Kramer HM, Curhan G. The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002;40: 37-42.
6. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health 2007;10: 231-237.
7. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35.
8. Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N. The experience and impact of living with gout: A study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 2011;17:1-6.
9. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009;48:582-586.
10. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-1048.
11. Hirsch JD, Terkeltaub R, Khanna D, et al. Gout diseasespecific quality of life and the association with gout characteristics. Patient Relat Outcome Meas 2010;1:1-8.
12. Singh JA. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep 2009;11:154-160.
13. Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M. Co-morbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther 2011 Feb 10 [Epub ahead of print].
14. Primatesta P, Plana E, Rothenbacher D. Gout treatment and co-morbidities: A retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 2011; 12:103.
15. Novak S, Melkonian AK, Patel PA, Kleinman NL, Joseph-Ridge N, Brook RA. Metabolic syndrome-related conditions among people with and without gout: Prevalence and resource use. Curr Med Res Opin 2007;23:623-630.
16. Singh JA, Strand V. Gout is associated with more co-morbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008; 67:1310-1316.
17. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006;22:1381-1389.
18. Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008;14:164-175.
19. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodr?guez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 2011;50:973-981.
20. Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009;25:1711-1719.
21. Brook RA, Kleinman NL, Su J, Corey-Lisle P, Iloeje UH. Absenteeism and productivity impact of treatment among employees with hepatitis-C. Am J Manag Care 2011;17:657-664.
22. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: Analysis from managed care data. J Clin Rheumatol 2006;12:61-65.
23. Blough D, Madden C, Hornbrook M. Modeling risk using generalized linear models. J Health Econ 1999;18:153-157.
24. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-934.
25. Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: Does serum uric acid level matter? J Rheumatol 2009;36:1032-1040.